Abstract
It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 77-88 |
| Number of pages | 12 |
| Journal | Breast Disease |
| Volume | 10 |
| Issue number | 1-2 |
| State | Published - Apr 1998 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
BRCA1 in clinical breast cancer. / Osborne, C. Kent; Elledge, Richard M; Brown, Powel H.; Hilsenbeck, Susan G.
In: Breast Disease, Vol. 10, No. 1-2, 04.1998, p. 77-88.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - BRCA1 in clinical breast cancer
AU - Osborne, C. Kent
AU - Elledge, Richard M
AU - Brown, Powel H.
AU - Hilsenbeck, Susan G.
PY - 1998/4
Y1 - 1998/4
N2 - It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.
AB - It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.
UR - http://www.scopus.com/inward/record.url?scp=0031897179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031897179&partnerID=8YFLogxK
M3 - Article
C2 - 15687551
AN - SCOPUS:0031897179
VL - 10
SP - 77
EP - 88
JO - Breast Disease
JF - Breast Disease
SN - 0888-6008
IS - 1-2
ER -